SGLT2 inhibitor canagliflozin shown to improve kidney oxygenation in diabetes patients

Type 2 diabetes can lead to diabetic kidney disease, but a class of drugs that cause the kidneys to remove glucose through urine has been gaining attention.

Data Insights – Pharmaceutical Technology

By Company Name No Filter Selected Bristol-Myers Squibb (697) Merck (512) Novartis (391) AstraZeneca (345) F. Hoffmann-La Roche (297) AbbVie (271) Pfizer (266) BeiGene (216)

November 20, 2023

Inside CVS Caremark’s move that broke Humira’s hold on the market

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) For the first time in April, biosimilars

May 9, 2024

Harnessing AI to Navigate the Shifting Landscape of Member Engagement

Amanda Bury, Chief Commercial Officer at Infermedica The healthcare landscape continues to evolve rapidly, driven by advancements in technology and the ongoing shift towards alternative

September 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.